Industrial Strategic Position Further Elevated,GF CSI All Share Health Care Index ETF(159938) Rises 0.79% Intraday

NewTimeSpace News: As of 13:49 on March 30, 2026, the CSI All-Share Healthcare Index (000991) rose 0.64%. Among its constituent stocks, 3S Bio Inc. surged 11.66%, Jiu'an Medical Co., Ltd. climbed 9.99%, Tonghua Dongbao Pharmaceutical Co., Ltd. advanced 6.63%, Intco Medical Co., Ltd. rose 6.52%, and Ocean Biomedical Co., Ltd. increased 5.59%. GF CSI All Share Health Care Index ETF(159938) rose 0.79% to a latest price of RMB 0.64. Over a longer period, as of March 27, 2026, the ETF had a cumulative increase of 0.48% in the past week. (The stocks listed above are only constituent stocks of the index and do not constitute any specific investment recommendation.)

In terms of liquidity, GF CSI All Share Health Care Index ETFrecorded an intraday turnover rate of 0.84% with a trading volume of RMB 43.7957 million. Over a longer period, as of March 27, the ETF had an average daily trading volume of RMB 60.9709 million in the past week.

In terms of scale, the latest size of GF CSI All Share Health Care Index ETFreached RMB 5.176 billion, a new high in the past month. (Data source: Wind)

In terms of capital flow, GF CSI All Share Health Care Index ETFsaw a latest net capital outflow of RMB 3.1208 million. Over a longer period, there were 4 days of net capital inflow in the past 5 trading days, with a total net inflow of RMB 148 million and an average daily net inflow of RMB 29.5694 million. (Data source: Wind)

Data showed that leveraged funds have continued to build positions in the ETF. The latest margin purchase volume of GF CSI All Share Health Care Index ETFreached RMB 1.2978 million, with the latest margin balance standing at RMB 29.04 million. (Data source: Wind)

As of March 27, the net asset value of GF CSI All Share Health Care Index ETFhas risen 1.92% in the past two years. In terms of earnings capacity, as of March 27, 2026, since its inception, the ETF has achieved a maximum monthly return of 22.34%, a longest consecutive monthly gain of 8 months with a cumulative increase of 67.34% during the period, a rise-fall month ratio of 72:63, and an average return of 5.58% in rising months. As of March 27, 2026, the ETF has achieved an annualized return of 1.29% exceeding the benchmark since its inception.

In terms of drawdown, as of March 27, 2026, GF CSI All Share Health Care Index ETFhad a relative drawdown of 0.06% against the benchmark since the start of the year.

In terms of fees, the management fee rate of GF CSI All Share Health Care Index ETFis 0.50% and the custodian fee rate is 0.10%.

In terms of tracking accuracy, as of March 27, 2026, the tracking error of GF CSI All Share Health Care Index ETFin the past month was 0.009%.

From the valuation perspective, the latest price-to-earnings ratio (PE-TTM) of the CSI All-Share Healthcare Index tracked by GF CSI All Share Health Care Index ETFis only 30.85 times, at the 3.66% quantile of the past year. That is, the valuation is lower than that in more than 96.34% of the time in the past year, standing at a historically low level.

GF CSI All Share Health Care Index ETFclosely tracks the CSI All-Share Healthcare Index. The CSI All-Share Industry Select Index Series selects listed companies that meet certain liquidity and market capitalization screening criteria from the CSI All-Share Industries as index samples, reflecting the overall performance of representative and investable listed company securities in various industries.

Data showed that as of February 27, 2026, the top 10 weight stocks of the CSI All-Share Healthcare Index (000991) were Jiangsu Hengrui Medicine Co., Ltd., WuXi AppTec Co., Ltd., Mindray Medical International Limited, United Imaging Healthcare Co., Ltd., Yunnan Baiyao Group Co., Ltd., Aier Eye Hospital Group Co., Ltd., Zhangzhou Pientzehuang Pharmaceutical Co., Ltd., Zhejiang NHU Co., Ltd., Sichuan Kelun Pharmaceutical Co., Ltd. and Fosun Pharmaceutical (Group) Co., Ltd. in turn, accounting for a total of 39.02% of the index weight. (The stocks listed above are only constituent stocks of the index and do not constitute any specific investment recommendation.)

GUOSHENG FINANCE stated that the 2026 Government Work Report listed biomedicine as a "new emerging pillar industry" for the first time, further elevating the industrial strategic position. Meanwhile, the first version of the commercial insurance innovative drug catalog has been officially launched, the multi-level payment system of "new medical insurance + commercial insurance" is being accelerated, and the payment environment for innovative drugs is continuously optimized.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.